One Mind Accelerator

One Mind Accelerator

One Mind Accelerator was launched as an initiative of the One Mind Foundation, a non-profit organization focused on accelerating brain health research and translating it into clinical practice. The program connects early-stage mental health startups with a network of researchers, clinicians, and investors who can help validate their science and scale their businesses. The accelerator's founding premise addresses the chronic underinvestment in serious mental illness — an area where patient need far exceeds the flow of venture dollars. The accelerator targets seed-stage companies building solutions for conditions including depression, anxiety, schizophrenia, bipolar disorder, PTSD, and substance use disorders. It participates in direct investments of $100,000 per company during its intensive 12-week program, which includes product development support, clinical trial design advisement, and introductions to follow-on investors. Portfolio companies have included NeuroFlow, a behavioral health integration platform, and Heading Health, a psychedelic-assisted therapy provider expanding access to novel treatments. The program sources companies nationally, with particular density on both US coasts. Beyond the capital, One Mind Accelerator provides companies with access to its scientific advisory network, corporate pilot opportunities, and the legacy of the One Mind Foundation's research consortium. The accelerator has also cultivated relationships with follow-on venture firms like General Catalyst and what-if ventures, which co-lead rounds for graduates. By embedding companies within a broader brain-health ecosystem, the accelerator aims to de-risk these investments for downstream institutional backers who might otherwise wait for later clinical validation. What differentiates One Mind Accelerator from a standard health-tech incubator is its non-profit chassis. Unlike a traditional venture fund, the accelerator operates under the auspices of a 501(c)(3) research foundation, allowing it to prioritize patient impact over return multiples in its earliest-stage diligence. This structure attracts founders with deep scientific backgrounds who might resist the dilution or commercial pressure of a conventional VC accelerator — creating a pipeline of companies that are often overlooked by for-profit early-stage investors until they have derisked their clinical hypotheses.